These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 15799209

  • 1. Treatment of microalbuminuria in patients with type 2 diabetes mellitus.
    Jerums G, MacIsaac RJ.
    Treat Endocrinol; 2002; 1(3):163-73. PubMed ID: 15799209
    [Abstract] [Full Text] [Related]

  • 2. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
    Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, DAIS Investigators.
    Am J Kidney Dis; 2005 Mar; 45(3):485-93. PubMed ID: 15754270
    [Abstract] [Full Text] [Related]

  • 3. Systematic review on urine albumin testing for early detection of diabetic complications.
    Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.
    Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
    [Abstract] [Full Text] [Related]

  • 4. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes.
    Mogensen CE.
    J Intern Med; 2003 Jul; 254(1):45-66. PubMed ID: 12823642
    [Abstract] [Full Text] [Related]

  • 5. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.
    McKenna K, Thompson C.
    Scott Med J; 1997 Aug; 42(4):99-104. PubMed ID: 9507584
    [Abstract] [Full Text] [Related]

  • 6. Drug treatment for hypertensive patients in special situations: diabetes and hypertension.
    Mogensen CE.
    Clin Exp Hypertens; 1999 Aug; 21(5-6):895-906. PubMed ID: 10423111
    [Abstract] [Full Text] [Related]

  • 7. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D.
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [Abstract] [Full Text] [Related]

  • 8. Preventing end-stage renal disease.
    Mogensen CE.
    Diabet Med; 1998 Mar; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [Abstract] [Full Text] [Related]

  • 9. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
    Donnelly R, Yeung JM, Manning G.
    J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161
    [Abstract] [Full Text] [Related]

  • 10. [Microalbuminuria: cardiovascular and renal risk factors underestimated in clinical practice].
    Zanella MT.
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):313-21. PubMed ID: 16767297
    [Abstract] [Full Text] [Related]

  • 11. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT, Ribeiro AB.
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [Abstract] [Full Text] [Related]

  • 12. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME.
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [Abstract] [Full Text] [Related]

  • 13. WITHDRAWN: Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
    Lovell HG.
    Cochrane Database Syst Rev; 2007 Jul 18; (1):CD002183. PubMed ID: 17636698
    [Abstract] [Full Text] [Related]

  • 14. Time to abandon microalbuminuria?
    Ruggenenti P, Remuzzi G.
    Kidney Int; 2006 Oct 18; 70(7):1214-22. PubMed ID: 16871239
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
    Morikawa A, Ishizeki K, Iwashima Y, Yokoyama H, Muto E, Oshima E, Sekiguchi M, Miura T, Itoh H, Haneda M.
    Clin Exp Nephrol; 2011 Dec 18; 15(6):848-53. PubMed ID: 21823043
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
    Lovell HG.
    Cochrane Database Syst Rev; 2001 Dec 18; (1):CD002183. PubMed ID: 11279757
    [Abstract] [Full Text] [Related]

  • 17. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A, Bashir K, Anwar E.
    Nepal Med Coll J; 2007 Jun 18; 9(2):79-83. PubMed ID: 17899953
    [Abstract] [Full Text] [Related]

  • 18. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Jun 18; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 19. Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor.
    Weir MR.
    J Clin Hypertens (Greenwich); 2004 Mar 18; 6(3):134-41; quiz 142-3. PubMed ID: 15010646
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R, Tonolo G.
    J Am Soc Nephrol; 2002 Nov 18; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.